Efficacy Analysis And Study Of Medication Rules Of 200 Cases Of Chronic Kidney Disease Stage 3-5 Spleen And Kidney Deficiency And Wet Turbidity And Stasis Blood Type

Objective: 1.Through a comprehensive retrospective analysis of the clinical data of200 patients with stage 3-5(non-dialysis)of chronic kidney disease with spleen and kidney deficiency and wet turbidity and stasis blood type,the clinical efficacy of TCM dialectical treatment of CKD was observed;2.Use the TCM inheritance auxiliary platform system to summarize and summarize the drugs in detail,and explore the characteristics of the composition of the spleen and kidney deficiency and wet turbid blood type of chronic kidney disease stage 3-5(non-dialysis),so as to provide an effective plan for the clinical treatment of chronic kidney disease.Methods: 1.Using retrospective clinical analysis methods,200 patients with chronic kidney disease 3-5(non-dialysis)diagnosed as chronic kidney disease in the outpatient and inpatient departments of the Second Department of Renal Department of Heilongjiang Provincial Hospital of Traditional Chinese Medicine from September 2018 to December2020 were selected,and 200 patients with spleen and kidney deficiency and wet turbidity and stasis blood type were selected,and the patient data that met the criteria were screened in strict accordance with the established inclusion and exclusion criteria,and the patient data that met the criteria were analyzed using SPSS26.0 software for detailed statistical analysis.After 8 weeks of continuous medication and self-control,the changes in laboratory indicators such as serum creatinine,urea nitrogen,uric acid,urine microalbumin and 24-hour urine protein quantification before and after treatment were analyzed,as well as the changes in clinical symptoms and TCM symptoms before and after treatment.2.Use the TCM inheritance assistance platform system to comprehensively summarize and analyze the prescription rules for the treatment of chronic kidney disease stage 3-5 spleen and kidney deficiency and wet turbid blood type.Results: 1.A total of 200 patients with chronic kidney disease stage 3-5(non-dialysis)with spleen and kidney deficiency and wet turbidity and stasis blood type were included in this project,including 118 male patients(59%),82 female patients(41%),and the ratio of male to female patients was 1.44:1.The age of the patients was mainly concentrated in 61-70 years old,accounting for 31.5%.Male patients are mainly concentrated in 51-60 years old,and female patients are mainly concentrated in 61-70 years old,with an average age of 56.38± 12.76 years.The distribution of primary disease in patients,of which chronic glomerulonephritis(50.5%),diabetic nephropathy(19.5%),and hypertensive renal impairment(11.5%)are in the top three.Patients with a course distribution,40% of patients with a course of 1-5 years,and 28.5% of patients with a course of < 1 year.The 200 patients with CKD were mainly distributed in the CKD5 stage,accounting for 36.5%.2.Renal function indicators(Scr,BUN,UA)and e GFR,4 weeks of treatment,8 weeks of treatment and pre-treatment and each other,the difference was statistically significant(P<0.05);UTP,MALB,PTH and Hb at 4 weeks of treatment and 8 weeks of treatment were statistically significant(P<0.05);there was no statistical difference between K,Ca and P at 4 weeks of treatment compared with before treatment(P>0.05).The 8 weeks of treatment were compared with the 8 weeks of treatment before treatment and the 8 weeks of treatment and 4weeks of treatment,and the difference was statistically significant(P<0.05).3.Evaluation of clinical efficacy before and after treatment: the total effective rate of clinical overall efficacy after 8 weeks of treatment was 79%,the total effective rate of clinical efficacy of TCM was77%,and the total integral of TCM syndrome after treatment decreased significantly compared with that before treatment(P<0.05).4.According to the statistics of the TCM inheritance assistance platform system,the frequency of drug application from high to low is Dang Ginseng,Poria Poria,Astragalus,Dogwood,Cooked Ground Yellow,Yam,Bayan Tian,Danshen,Peony Peel,Wolfberry,etc.Based on the analysis of the law of the combination of chinese medicine prescription drugs,the drug combinations with high frequency are dang ginseng and astragalus,dang ginseng,poria,astragalus,poria,dang ginseng,astragalus,poria,dogwood,dang ginseng,ripe ground yellow,astragalus,astragalus,astragalus,astragalus,astragalus,etc.The core drug combinations are Qi Shi-Golden Cherry Seed-Chuan Qian;Qian Shi-Golden Cherry Seed-Mulberry;Huang Lian-Citrus Aurantium-Magnolia;Golden Cherry Seed-Mulberry-Half Branch Lotus;Silk Seed-Forsythia-Angelica;Fenugreek-Perilla-Bayantian and so on.Different drug combinations and new prescriptions have been formed.Conclusion: 1.The treatment principle of chronic kidney disease 3-5 stage spleen and kidney deficiency and wet turbidity and stasis blood type is to tonify the spleen and kidneys and activate blood diarrhea.2.Traditional Chinese medicine dialectical treatment of chronic kidney disease can effectively reduce the quantitative amount of urine protein,reduce serum creatinine,urea nitrogen,uric acid,improve glomerular filtration rate,improve clinical symptoms,delay the progression of the disease,and protect residual kidney function.3.Use the TCM inheritance assistance platform system to conduct data analysis to obtain drugs,drug combinations and core drug combinations with high to low drug frequency.Summarize the characteristics of drug formulations,and provide an effective program for the clinical treatment of CKD.